Hosted on MSN24m
Regeneron Gets Positive CHMP Opinion for Multiple Myeloma Drug
Regeneron Pharmaceuticals, Inc. REGN obtained positive opinion for its pipeline candidate linvoseltamab from the European ...
Hosted on MSN4d
Regeneron makes second bid for blood cancer therapy approval
The FDA will issue a decision on odronextamab’s accelerated approval in relapsed/refractory follicular lymphoma by 30 July ...
Yahoo Finance13d
FDA to review Sanofi and Regeneron’s Dupixent sBLA for bullous pemphigoid
Sanofi and Regeneron’s blockbuster biologic Dupixent (dupilumab) is poised for yet another label expansion, this time for the rare autoimmune skin disorder bullous pemphigoid (BP). The US Food ...
Bloomberg L.P.7d
Regeneron’s Gene Therapy Improves Hearing in Deaf Children
A gene therapy from Regeneron Pharmaceuticals Inc. improved hearing in nearly all deaf children in a clinical trial, results that could allow the company to seek regulatory approval for the one ...
Reuters27d
Regeneron beats quarterly estimates on eczema drug demand; launches dividend program
Feb 4 (Reuters) - Regeneron Pharmaceuticals (REGN.O), opens new tab beat fourth-quarter sales and profit estimates on Tuesday, on continuing demand for its eczema treatment, Dupixent, and ...
Investopedia13d
FDA To Review Teva and Alvotech Drug That Could Compete With Regeneron's Eylea
SOPA Images / Contributor / Getty Images Teva Pharmaceutical ... The treatment is a biosimilar that could compete with Regeneron Pharmaceuticals’ Eylea. Teva and Alvotech have been working ...